Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.36 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGAV | P06756 | 1/20 | 0.36 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.35 |
| ▸ | ACP3 | P15309 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13538579 | 0.83 | ACP3 (0.41) | PARP1LTA4HALDH1A1LMNACYP1A2 | |
| SCHEMBL3271284 | 0.81 | SIGMAR1 (0.48) | PARP1LTA4HALDH1A1LMNACYP1A2 | |
| SCHEMBL19529577 | 0.81 | LTA4H (0.37) | PARP1LTA4HALDH1A1LMNACYP1A2 | |
| SCHEMBL18550519 | 0.78 | LOXL2 (0.47) | PARP1ALDH1A1LMNACYP1A2ALOX15 | |
| SCHEMBL13538576 | 0.78 | MEN1 (0.41) | PARP1LTA4HALDH1A1LMNACYP1A2 | |
| SCHEMBL18551430 | 0.76 | HPGD (0.32) | — | |
| SCHEMBL10262287 | 0.75 | CYP1A2 (0.53) | PARP1LTA4HALDH1A1CYP1A2SIGMAR1 | |
| SCHEMBL13164692 | 0.74 | ALDH1A1 (0.49) | PARP1LTA4HALDH1A1LMNACYP1A2 | |
| SCHEMBL8443205 | 0.73 | LMNA (0.48) | PARP1LTA4HALDH1A1LMNAALOX15 | |
| SCHEMBL3440308 | 0.73 | LOXL2 (0.50) | PARP1LTA4HALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221202-B2 | Annelated phenoxyacetamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-03-05 | — | — | US | disclosed |
| US-20170313732-A1 | NOVEL ANNELATED PHENOXYACETAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313732-A1 | NOVEL ANNELATED PHENOXYACETAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2017-11-02 | — | — | US | disclosed |
| US-20170050992-A1 | NOVEL ANNELATED PHENOXYACETAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-23 | — | — | US | disclosed |
| US-20170050992-A1 | NOVEL ANNELATED PHENOXYACETAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313732-A1 | NOVEL ANNELATED PHENOXYACETAMIDES | EP300, NAT1, AADAC | PARP1 2763/4885LTA4H 2119/4885ALDH1A1 113/4885 |
| US-10221202-B2 | Annelated phenoxyacetamides | EP300, NAT1, REN | PARP1 2056/4885LTA4H 2689/4885ALDH1A1 179/4885 |
| US-20170050992-A1 | NOVEL ANNELATED PHENOXYACETAMIDES | EP300, NAT1, AADAC | PARP1 2582/4885LTA4H 1920/4885ALDH1A1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.